A 30-minute valve replacement surgery, Peijia Medical cracks the 'heart' challenge!
Recently, the production line of Peijia Medical at No. 8 Yangjiatian Road in Suzhou Industrial Park has been even hotter than the weather.
Since the TaurusTrio transcatheter aortic valve system was approved last December, orders have been pouring in like snowflakes. Although the first-half shipment volume far exceeded the planned target, it still falls far short of meeting clinical demand. Doctors' WeChat messages urging for orders frequently arrive: "The patient can't wait, please ship as soon as possible." Behind this is the desire of thousands of aortic regurgitation patients for minimally invasive surgery, and also doctors' highest trust in this innovative product.
What's so magical about this product that has the market "going crazy" for it?
Yi Kejing, Senior Vice President of R&D and Operations at Peijia Medical Technology (Suzhou) Co., Ltd., explained that the heart's aortic valve is like a door. If the door doesn't close tightly, blood flows backward. This is aortic regurgitation, which forces the heart to work overtime, leading to myocardial hypertrophy and heart enlargement over time. In severe cases, it can cause heart failure.
Traditional interventional valve replacement mainly relies on hard lumps (calcification) growing on the valve frame to secure the new valve. But for patients with a simple "failure to close tightly," the frame is smooth. The new valve, once placed, has nowhere to "hook" onto, making displacement very likely. In the past, these patients often had no choice but open-heart surgery, bearing significant surgical trauma.
The birth of TaurusTrio is precisely to solve this "nowhere to land" dilemma. It has the following advantages:
"Holds Firm"
Its core innovation can be figuratively understood as equipping the valve with three exclusive "intelligent positioning keys."
These three positioning keys are like precision mechanical grippers that can accurately clamp onto the three sinus floors of the heart's native valve. Just like a climber finding three stable footholds, no matter how violently the heart beats, the valve remains firmly fixed, avoiding the risk of valve migration.
"Large Windows" Leave a Path for Future Treatment
The coronary arteries above the heart are responsible for supplying blood to the heart. If the mesh of the prosthetic valve is too dense, it can easily block the coronary artery openings after implantation. If a patient later develops coronary artery blockage, and the doctor wants to perform a minimally invasive procedure through the vessels, they might not even find a path, which would be very troublesome.
TaurusTrio is designed with three large "windows" — in medical terms, this is called an open-cell stent structure. This design leaves ample room for future treatments — even if the patient has future heart vessel problems, doctors can easily pass catheters through these spacious "windows" for rescue or treatment.
Extremely Flexible Delivery System, Short Procedure Time
On the operating table, the delivery system in the doctor's hand is like having a "soul." It can achieve 360° rotation and 270° bending. This extreme flexibility allows doctors, like manipulating a nimble thread, to easily deliver the valve to the predetermined position and precisely release the "intelligent positioning keys."
What was once a complex, high-risk procedure can now be completed in just 25-30 minutes, with a success rate exceeding 99%.
Currently, Peijia Medical has built a diagnostic and treatment network covering the "aortic valve, mitral valve, and tricuspid valve" across all anatomical positions. Through a tiered and differentiated product matrix for transcatheter aortic valve replacement (TAVR), the company has become the domestic "leader" in the industry within just a few years. The market share of its already-launched TAVR products in China's transfemoral TAVR market has steadily increased from less than 5% in 2021 to currently holding the "top spot" in the domestic market.
In the next three years, this Suzhou-based, independently cultivated high-end medical device company will continue to launch major new products, filling gaps in the industry.
Source: Suzhou Daily
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
